Boundless Bio, Inc. Common Stock
BOLDBoundless Bio, Inc. (BOLD) is a biotechnology company focused on developing targeted therapies for cancer and other parts of the immune system. The company leverages its proprietary platforms to identify and develop innovative treatments aimed at addressing unmet medical needs.
Company News
Boundless Bio presented preclinical data supporting BBI-940, an oral kinesin degrader, as a potential first-in-class therapy for advanced or metastatic breast cancers. The compound targets a novel kinesin protein essential for extrachromosomal DNA (ecDNA) segregation in cancer cells but non-essential in healthy cells. Preclinical studies demonstr...
Boundless Bio announced financial results for 2025 with $107.6 million in cash providing runway through mid-2028. The company's lead program BBI-940, a first-in-class oral Kinesin degrader, is actively enrolling patients in the KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR. The company reduced R&D expenses to $44.8 million for 2025 and ...
Boundless Bio announced that its novel Kinesin degrader BBI-940 received IND acceptance, with first-in-human clinical trials expected to begin in the first half of 2026. The company extended its operating runway through portfolio prioritization, including discontinuation of the POTENTIATE trial. CEO Zachary Hornby will participate in upcoming bio...
Boundless Bio, a clinical-stage oncology company, reported its Q1 2025 financial results and provided updates on its pipeline. The company has a cash position of $138.3 million, which is expected to fund operations into 2027. Boundless Bio is advancing its BBI-355 program, a CHK1 inhibitor, and its novel Kinesin program, with key milestones expec...
Boundless Bio, a clinical-stage oncology company, announced that its President and CEO will participate in Needham's Virtual Healthcare Conference. The company is developing an oral inhibitor of checkpoint kinase 1 (CHK1) to target extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
